Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients Outcome

Conclusion: The 177Lu-PSMA-617 clearance rate from mCRPC metastases appears to be a relevant prognosticator of response and survival, with faster clearing possibly signaling a shorter radiopharmaceutical residence time and absorbed dose. Dual-time-point analysis appears to be a feasible and readily available approach to estimate the likelihood of response and patients’ survival.

Source: Journal of Nuclear Medicine - September 1, 2023 Category: Nuclear Medicine Authors: Straub, M., Kupferschlager, J., Serna Higuita, L. M., Weissinger, M., Dittmann, H., la Fougere, C., Fiz, F. Tags: Clinical Investigations Source Type: research